Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Ash 2021 roundup
Evaluate Vantage's coverage of the Ash 2021 congress.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
SITC 2021 – ALX Oncology's unpleasant double dip
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.
Trillium gets a buyout while it's down
The latest deal over a CD47 asset has got investors wondering who could be next.